PMID- 22079855
OWN - NLM
STAT- MEDLINE
DCOM- 20120611
LR  - 20220318
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 59
IP  - 1
DP  - 2012 Jan
TI  - Low molecular weight heparin versus unfractionated heparin in patients with acute 
      non-ST-segment elevation myocardial infarction undergoing percutaneous coronary 
      intervention with drug-eluting stents.
PG  - 22-9
LID - 10.1016/j.jjcc.2011.09.005 [doi]
AB  - BACKGROUND: Whether low molecular weight heparin (LMWH) enoxaparin is equivalent 
      to unfractionated heparin (UFH) in patients with non-ST-segment elevation 
      myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention 
      (PCI) with drug-eluting stents (DES) remains unclear. METHODS: A total of 2397 
      NSTEMI patients who underwent PCI with DES received either LMWH [n=1178, 
      subcutaneous enoxaparin 1 mg/kg, b.i.d., initiated after the patient's arrival 
      and continued until 3-5 days after PCI plus reduced dose of UFH (50-70 U/kg) 
      during PCI] or UFH (n=1219, 24,000U/day infusion, initiated after the patient's 
      arrival and continued until at least 48 h after PCI). The bleeding events and 
      clinical outcomes during in-hospital and at 8 months were compared. RESULTS: 
      Enoxaparin group had similar incidences of cardiac death, total death, and total 
      major adverse cardiac events (MACE) at 8 months compared with UFH group. The 
      incidences of major and minor bleeding events were also similar between the two 
      groups. Multivariable Cox regression analysis showed that enoxaparin group had 
      similar incidences of cardiac death [adjusted odds ratio (OR) 1.16, 95% 
      confidence interval (CI) 0.64-2.10, p=0.620], total death (adjusted OR 1.08, 95% 
      CI 0.66-1.76, p=0.760), and total MACE (adjusted OR 0.94, 95% CI 0.69-1.28, 
      p=0.692) at 8 months as compared with UFH group. CONCLUSIONS: Enoxaparin with 
      reduced dose of UFH only during PCI as an adjunctive antithrombotic therapy in 
      NSTEMI patients undergoing PCI with DES was safe and showed comparable 8-month 
      clinical outcomes as compared with UFH alone.
CI  - Copyright (c) 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Li, Yong-Jian
AU  - Li YJ
AD  - Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
FAU - Rha, Seung Woon
AU  - Rha SW
FAU - Chen, Kang-Yin
AU  - Chen KY
FAU - Jin, Zhe
AU  - Jin Z
FAU - Wang, Lin
AU  - Wang L
FAU - Ramasamy, Sureshkumar
AU  - Ramasamy S
FAU - Poddar, Kanhaiya L
AU  - Poddar KL
FAU - Minami, Yoshiyasu
AU  - Minami Y
FAU - Park, Ji-Young
AU  - Park JY
FAU - Choi, Cheol Ung
AU  - Choi CU
FAU - Oh, Dong Joo
AU  - Oh DJ
FAU - Jeong, Myung Ho
AU  - Jeong MH
CN  - Korea Acute Myocardial Infarction Registry Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111112
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - *Drug-Eluting Stents
MH  - *Electrocardiography
MH  - Enoxaparin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*physiopathology/*therapy
MH  - Treatment Outcome
FIR - Jeong, Myung Ho
IR  - Jeong MH
FIR - Kim, Young Jo
IR  - Kim YJ
FIR - Kim, Chong Jin
IR  - Kim CJ
FIR - Cho, Myeong Chan
IR  - Cho MC
FIR - Ahn, Young Keun
IR  - Ahn YK
FIR - Kim, Jong Hyun
IR  - Kim JH
FIR - Chae, Shung Chull
IR  - Chae SC
FIR - Hur, Seung Ho
IR  - Hur SH
FIR - Seong, In Whan
IR  - Seong IW
FIR - Hong, Taek Jong
IR  - Hong TJ
FIR - Choi, Dong Hoon
IR  - Choi DH
FIR - Chae, Jei Keon
IR  - Chae JK
FIR - Rhew, Jae Young
IR  - Rhew JY
FIR - Kim, Doo Il
IR  - Kim DI
FIR - Chae, In Ho
IR  - Chae IH
FIR - Yoon, Jung Han
IR  - Yoon JH
FIR - Koo, Bon Kwon
IR  - Koo BK
FIR - Kim, Byung Ok
IR  - Kim BO
FIR - Lee, Myoung Yong
IR  - Lee MY
FIR - Kim, Kee Sik
IR  - Kim KS
FIR - Hwang, Jin Yong
IR  - Hwang JY
FIR - Oh, Seok Kyu
IR  - Oh SK
FIR - Lee, Nae Hee
IR  - Lee NH
FIR - Jeong, Kyoung Tae
IR  - Jeong KT
FIR - Tahk, Seung Jea
IR  - Tahk SJ
FIR - Bae, Jang Ho
IR  - Bae JH
FIR - Rha, Seung Woon
IR  - Rha SW
FIR - Park, Keum Soo
IR  - Park KS
FIR - Han, Kyoo Rok
IR  - Han KR
FIR - Ahn, Tae Hoon
IR  - Ahn TH
FIR - Kim, Moo Hyun
IR  - Kim MH
FIR - Yang, Ju Young
IR  - Yang JY
FIR - Rhim, Chong Yun
IR  - Rhim CY
FIR - Gwon, Hyeon Cheol
IR  - Gwon HC
FIR - Park, Seong Wook
IR  - Park SW
FIR - Koh, Young Youp
IR  - Koh YY
FIR - Joo, Seung Jae
IR  - Joo SJ
FIR - Kim, Soo Joong
IR  - Kim SJ
FIR - Jin, Dong Kyu
IR  - Jin DK
FIR - Cho, Jin Man
IR  - Cho JM
FIR - Cho, Jeong Gwan
IR  - Cho JG
FIR - Chung, Wook Sung
IR  - Chung WS
FIR - Jang, Yang Soo
IR  - Jang YS
FIR - Seung, Ki Bae
IR  - Seung KB
FIR - Park, Seung Jung
IR  - Park SJ
EDAT- 2011/11/15 06:00
MHDA- 2012/06/12 06:00
CRDT- 2011/11/15 06:00
PHST- 2011/05/15 00:00 [received]
PHST- 2011/09/13 00:00 [revised]
PHST- 2011/09/29 00:00 [accepted]
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/06/12 06:00 [medline]
AID - S0914-5087(11)00208-5 [pii]
AID - 10.1016/j.jjcc.2011.09.005 [doi]
PST - ppublish
SO  - J Cardiol. 2012 Jan;59(1):22-9. doi: 10.1016/j.jjcc.2011.09.005. Epub 2011 Nov 
      12.